September 14, 2005 10:18 ET

Update on Pivotal Trial of Nymox's NX-1207 For Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Sep 14, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide an update on its ongoing multi-center Phase 2 trial of NX-1207. A recently updated review of overall safety data filed with the FDA has revealed no serious drug side effects or safety issues thus far. More than 20 clinical sites across the U.S. are involved in the trial to date and patient accrual has proceeded as expected. The pivotal Phase 2 trial of NX-1207 is expected to be completed later this year.

NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH) which the company believes shows good promise as a potential first-line treatment for BPH. In two completed trials in the U.S. to date, the drug has shown highly significant efficacy without significant adverse side effects or safety problems.

In the Phase 1-2 trials to date, the subjects treated with NX-1207 showed a statistically significant overall mean symptom improvement after one month of 6.87 points (compared to 0.5 for controls) and a statistically significant shrinkage in prostate size (mean loss of over 11 grams). There were no significant adverse side effects from the drug in these trials. Significantly, subjects followed for up to two years post-treatment showed even further statistically significant symptom improvement of 9.3 points.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: nfo@nymox.com, or 800 936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX